UNSPSC 51433602: Minoxidil

This classification denotes a vasodilating agent and antihypertensive agent with the molecular formula C9H15N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5965120SH1, chemically known as 2,6-diamino-4-piperidinopyrimidin-1-oxid but generally known as minoxidil, which bears US NIH Compound Identifier 4201. European Medicines Agency schedules Minoxidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08982MIG.

UNSPSC 51433602 Minoxidil is a Commodity code that in practice encompasses advanced life support and emergency medications supplied to municipal fire and rescue services and state health agency pharmacy benefit programs, rather than the topical hair-loss treatment the code name suggests. State and local governments soliciting under this code are purchasing sealed-bid supplies of injectable medications—epinephrine, adenosine, labetalol, diltiazem, and related formulations—for emergency medical use, as well as establishing framework agreements for generic pharmaceuticals and over-the-counter products distributed through state and local health systems. The issuing bodies include municipal purchasing departments (cities), state health and human services agencies, and multistate cooperative purchasing alliances; the City of Tampa and the Texas Health and Human Services Commission are recent solicitors, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a two-year framework covering multiple participating jurisdictions.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications required within ten calendar days of order, with a one-year contract term and two optional one-year renewals, estimated at $40,000.00 and carrying a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission posted an RFI on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer pharmacy programs outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's MMCAP issued an RFP due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with pricing evaluation weighted 75 percent on competitiveness and effective contract date of July 1, 2026.